StageAcq - Pending | Acquired
SomaLogic is a protein biomarker discovery and clinical diagnostics company leveraging its Slow Off-rate Modified Aptamer (SOMAmer) technology. The company aims to develop and commercialize breakthrough clinical diagnostic products that will transform healthcare; and drive the discovery and development of new therapeutics by facilitating protein biomarker discovery and validation.
Missing: SomaLogic's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: SomaLogic's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing SomaLogic
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned SomaLogic in 2 CB Insights research briefs, most recently on Jan 24, 2023.
Expert Collections containing SomaLogic
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
SomaLogic is included in 7 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
SomaLogic has filed 109 patents.
The 3 most popular patent topics include:
- Molecular biology
- Nucleic acids
Molecular biology, Nucleic acids, Biotechnology, DNA, RNA
Molecular biology, Nucleic acids, Biotechnology, DNA, RNA
Latest SomaLogic News
Mar 13, 2023
Boulder, Colorado, UNITED STATES BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. This work builds on a successful history of SomaScan® Platform utilization in some of the world’s largest population proteomics biobank projects, including the EPIC , MESA , Fenland, Whitehall II, HUNT3, CRIC, COPD Gene, Spiromics, deCODE and ARIC datasets. Professor Zhengming Chen, Richard Peto Professor of Epidemiology at Oxford Population Health and UK-Principal Investigator of the China Kadoorie Biobank, said “The large-scale application of proteomics assays in big population biobanks such as CKB will be a game changer. Building on the experience gained in these initial 4,000 samples, we will seek to extend the use of the proteomic assay to a much larger number of samples in the near future.” The China Kadoorie Biobank ( www.ckbiobank.org ) was established to investigate the main genetic and environmental causes of common chronic diseases in the Chinese population. Between 2004 and 2008, over 510,000 adults were recruited from ten geographically defined regions of China, with extensive data collection by questionnaire and physical measurements, and with long-term storage of blood samples for future study. All participants are now being monitored for fatal and non-fatal health outcomes through linkage with established registries and health insurance databases in the study areas. This large, well-established study will be a uniquely powerful and rich resource for investigating the main causes of many common chronic diseases over the next few decades, and the information generated has the potential to improve understanding of disease etiology, risk prediction and development of new treatments. The project is a long-term collaboration between Oxford Population Health, Peking University and the Chinese Academy of Medical Sciences. SomaLogic’s proprietary SomaScan Platform is designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 550,000 samples to date. About SomaLogic SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com . About Oxford Population Health Oxford Population Health (the Nuffield Department of Population Health) is a world-leading research institute, based at the University of Oxford, that investigates the causes and prevention of disease. We have over 750 staff, students and academic visitors working in a number of world-renowned population health research groups, including the Cancer Epidemiology Unit (CEU), Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), and the National Perinatal Epidemiology Unit (NPEU), and other groups working on public health, health economics, ethics and health record linkage. Oxford Population Health is also a key partner in the Oxford University Big Data Institute.
SomaLogic Frequently Asked Questions (FAQ)
When was SomaLogic founded?
SomaLogic was founded in 1999.
Where is SomaLogic's headquarters?
SomaLogic's headquarters is located at 2945 Wilderness Place, Boulder.
What is SomaLogic's latest funding round?
SomaLogic's latest funding round is Acq - Pending.
How much did SomaLogic raise?
SomaLogic raised a total of $590.99M.
Who are the investors of SomaLogic?
Investors of SomaLogic include CM Life Sciences II, Casdin Capital, Novartis Venture Funds, Redmile Group, Intermountain Ventures and 40 more.
Who are SomaLogic's competitors?
Competitors of SomaLogic include Actome, Intervenn Biosciences, Integrated Nano-Technologies, Integrated Diagnostics, Daktari Diagnostics and 13 more.
Compare SomaLogic to Competitors
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Quadraspec is changing the face of diagnostic medicine. Quadraspec's patented SDI label-free detection technology aims to permit the rapid analysis of up to 100 unique tests on up to 1,000 unique patients per hour. Quadraspec's , multiplex-capable diagnostics platform aims to allow high throughput, label-free, highly sensitive bioassays, and diagnostics.
Zoray Technologies Inc. is developing a multiplex immunoassay platform for life science research and clinical diagnostics. Immunoassays that identify the presence of specific protein biomarkers in blood, urine, or saliva constitute a vital tool in modern healthcare. Zoray's technology aims to enable many immunoassays to be multiplexed on to one small disposable chip. While multiplexed immunoassays are emerging in life science research, existing techniques require a labeling step that adds variability, inhibit high density arrays, and provide a less quantifiable signal. With simple, inexpensive, label-free protein array detection, Zoray expects to make a strong impact in molecular in vitro diagnostics with tests that aim to provide more information than is currently feasible.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
G-Nostics is a company in the field of personalised medicine based on the science of pharmacogenetics. The initial product is a diagnostic test, the NicoTest, focused on targeting treatment to aid smoking cessation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.